# Rolf Lewensohn

List of Publications by Year
in descending order



| 58 | 1,515 | 471061 17 | 329751 37 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 61 | 61 | 61 | 2215 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The association of four genetic variants with myelosuppression in gemcitabineâ€treated Japanese is not evident in gemcitabine/carboplatinâ€treated Swedes. Basic and Clinical Pharmacology and Toxicology, 2022, , . | 1.2 | 1 |
| 2 | Cytotoxic Alkylynols of the Sponge Cribrochalina vasculum: Structure, Synthetic Analogs and SAR Studies. Marine Drugs, 2022, 20, 265. | 2.2 | 3 |
| 3 | Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta OncolÃ³gica, 2022, 61, 869-873. | 0.8 | 1 |
| 4 | Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. Molecular Oncology, 2022, 16, 3620-3641. | 2.1 | 4 |
| 5 | EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 1010. | 1.7 | 8 |
| 6 | Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR. Cancers, 2021, 13, 922. | 1.7 | 15 |
| 7 | Multiplex immune protein profiling of fineâ€needle aspirates from patients with nonâ€smallâ€cell lung cancer reveals signatures associated with PDâ€L1 expression and tumor stage. Molecular Oncology, 2021, 15, 2941-2957. | 2.1 | 8 |
| 8 | The HILUS-Trialâ€"a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. Journal of Thoracic Oncology, 2021, 16, 1200-1210. | 0.5 | 92 |
| 9 | Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 2021, 13, 4164. | 1.7 | 5 |
| 10 | Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor. ACS Applied Materials & Interfaces, 2021, 13, 42513-42521. | 4.0 | 12 |
| 11 | In Response to Rosenberg etÂal. â€œThe Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Windowâ€. Journal of Thoracic Oncology, 2021, 16, e81-e82. | 0.5 | 0 |
| 12 | Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. Biosensors and Bioelectronics, 2021, 193, 113568. | 5.3 | 10 |
| 13 | Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc â€“ effects and side effects. Acta OncolÃ³gica, 2021, 60, 305-311. | 0.8 | 2 |
| 14 | Comparison and optimization of nanoscale extracellular vesicle imaging by scanning electron microscopy for accurate size-based profiling and morphological analysis. Nanoscale Advances, 2021, 3, 3053-3063. | 2.2 | 7 |
| 15 | Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics Journal, 2020, 20, 179-191. | 0.9 | 7 |
| 16 | Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers. Acta OncolÃ³gica, 2020, 59, 28-32. | 0.8 | 4 |
| 17 | Treatment patterns and survival outcomes for small-cell lung cancer patients â€“ a Swedish single center cohort study. Acta OncolÃ³gica, 2020, 59, 388-394. | 0.8 | 18 |
| 18 | Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study. Lung Cancer, 2020, 139, 111-117. | 0.9 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. Lung Cancer, 2020, 147, 106-114. | 0.9 | 5 |
| 20 | ALK-Brain Prognostic Indexâ€"Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases. Cancers, 2020, 12, 1804. | 1.7 | 3 |
| 21 | Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. Npj Systems Biology and Applications, 2020, 6, 25. | 1.4 | 9 |
| 22 | An immune gene expression signature distinguishes central nervous system metastases from primary tumours in nonâ€"small-cell lung cancer. European Journal of Cancer, 2020, 132, 24-34. | 1.3 | 14 |
| 23 | The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS ONE, 2020, 15, e0240973. | 1.1 | 18 |
| 24 | Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions. Acta OncolÃ³gica, 2019, 58, 1178-1186. | 0.8 | 24 |
| 25 | Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor. ACS Sensors, 2019, 4, 1399-1408. | 4.0 | 54 |
| 26 | miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochemical and Biophysical Research Communications, 2019, 511, 260-265. | 1.0 | 19 |
| 27 | Protein profiling of fineâ€needle aspirates reveals subtypeâ€associated immune signatures and involvement of chemokines in breast cancer. Molecular Oncology, 2019, 13, 376-391. | 2.1 | 28 |
| 28 | Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer, 2018, 120, 75-81. | 0.9 | 17 |
| 29 | Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment. International Journal of Radiation Oncology Biology Physics, 2018, 100, 174-187. | 0.4 | 6 |
| 30 | Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. Lung Cancer, 2018, 124, 45-52. | 0.9 | 53 |
| 31 | A fineâ€needle aspirationâ€based protein signature discriminates benign from malignant breast lesions. Molecular Oncology, 2018, 12, 1415-1428. | 2.1 | 15 |
| 32 | Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer. Acta OncolÃ³gica, 2018, 57, 231-238. | 0.8 | 9 |
| 33 | Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiation Oncology, 2017, 12, 206. | 1.2 | 92 |
| 34 | Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. Oncotarget, 2016, 7, 60332-60347. | 0.8 | 20 |
| 35 | SPACE â€" A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiotherapy and Oncology, 2016, 121, 1-8. | 0.3 | 270 |
| 36 | Melphalanâ€flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. Molecular Oncology, 2016, 10, 719-734. | 2.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research, 2016, 22, 366-373. | 3.2 | 20 |
| 38 | Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells. Oncotarget, 2016, 7, 50258-50276. | 0.8 | 20 |
| 39 | Preclinical activity of melflufen (J1) in ovarian cancer. Oncotarget, 2016, 7, 59322-59335. | 0.8 | 13 |
| 40 | Educational level and outcome in small-cell lung cancer (SCLC): A population-based study.. Journal of Clinical Oncology, 2016, 34, e20096-e20096. | 0.8 | 0 |
| 41 | Clinical significance of the tumor expression of PD-L1 in lung cancer.. Journal of Clinical Oncology, 2016, 34, e20031-e20031. | 0.8 | 0 |
| 42 | First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Investigational New Drugs, 2015, 33, 1232-1241. | 1.2 | 27 |
| 43 | DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer, 2015, 15, 628. | 1.1 | 23 |
| 44 | Toward Rare Blood Cell Preservation for RNA Sequencing. Journal of Molecular Diagnostics, 2015, 17, 352-359. | 1.2 | 3 |
| 45 | Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clinical Proteomics, 2015, 12, 8. | 1.1 | 31 |
| 46 | Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Nonâ€“Small Cell Lung Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 2941-2954. | 1.9 | 13 |
| 47 | Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1215-1224. | 0.8 | 9 |
| 48 | Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. Blood, 2010, 116, 1838-1838. | 0.6 | 0 |
| 49 | Individualized Multidrug Resistance In Acute Myeloid Leukemia. Blood, 2010, 116, 2491-2491. | 0.6 | 0 |
| 50 | Analysis of Î³H2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML. Blood, 2008, 112, 4854-4854. | 0.6 | 0 |
| 51 | Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene, 2002, 21, 65-77. | 2.6 | 10 |
| 52 | Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene, 2001, 20, 2877-2888. | 2.6 | 69 |
| 53 | A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus. Acta OncolÃ³gica, 2001, 40, 566-573. | 0.8 | 19 |
| 54 | Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. International Journal of Cancer, 2000, 89, 300-304. | 2.3 | 356 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Combined Treatment Modalities in Esophageal Cancer: Should chemotherapy be included?. Acta OncolÃ³gica, 1994, 33, 439-450. | 0.8 | 12 |
| 56 | Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226. European Journal of Haematology, 1991, 47, 161-167. | 1.1 | 13 |
| 57 | Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 63-67. | 1.0 | 1 |
| 58 | Efficacy of peptide bound m-l-sarcolysin (peptichemio) on melphalan resistant human myeloma cellsIn vitro. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 265-269. | 1.0 | 3 |